ArticleBritish journal of pharmacology2011
NPY receptors as potential targets for anti-obesity drug development.
Article in British journal of pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 133 citations in OpenAlex.
- Adipose Y5R mRNA is higher in obese than non-obese humans and is correlated with obesity parameters.Experimental biology and medicine (Maywood, N.J.) · 2018Trial
- Stabilized thioamide peptide agonists of the neuropeptide Y type 2 receptor for targeted cancer imaging.RSC chemical biology · 2026Article
- Evaluating methodological constraints in PET imaging of neuropeptide Y2 receptors with N-[EJNMMI radiopharmacy and chemistry · 2025Article
- Thyroid Response to Peripheral Endocrine Factors: Neuropeptide Y Influences Thyroid Function in the ReptileInternational journal of molecular sciences · 2025Article
- Leptin and G-protein coupled receptor (GPCR) signaling: Therapeutic potential in obesity.The Journal of biological chemistry · 2025Review
- Recent advances in reprogramming lactate metabolism in polycystic ovary syndrome.Journal of ovarian research · 2025Review
- Brain-Bone Axis in Physiological and Pathological Conditions.International journal of molecular sciences · 2025Review
- Transient ligand contacts of the intrinsically disordered N-terminus of neuropeptide YNature communications · 2025Article
- Intranasal Application of Peptides Modulating the Neuropeptide Y System.ACS pharmacology & translational science · 2025Article
- Obesity: exploring its connection to brain function through genetic and genomic perspectives.Molecular psychiatry · 2025Review
- Activity of the hypothalamic neuropeptide Y increases in adult and decreases in old rats.Scientific reports · 2024Article
- Revealing Molecular Mechanisms of the Bioactive Saponins from Edible Root ofPlants (Basel, Switzerland) · 2024Article
- 360-Degree Perspectives on Obesity.Medicina (Kaunas, Lithuania) · 2023Review
- Lateral hypothalamic leptin receptor neurons drive hunger-gated food-seeking and consummatory behaviours in male mice.Nature communications · 2023Article
- Hormonal Gut-Brain Signaling for the Treatment of Obesity.International journal of molecular sciences · 2023Review
- The Bidirectional Relationship of NPY and Mitochondria in Energy Balance Regulation.Biomedicines · 2023Review
- Article
- Neuroprotective Effects of Neuropeptide Y against Neurodegenerative Disease.Current neuropharmacology · 2022Review
- Activation of Neuropeptide Y2 Receptor Can Inhibit Global Cerebral Ischemia-Induced Brain Injury.Neuromolecular medicine · 2022Article
- Receptor-specific recognition of NPY peptides revealed by structures of NPY receptors.Science advances · 2022Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neuropeptide Y system has proven to be one of the most important regulators of feeding behaviour and energy homeostasis, thus presenting great potential as a therapeutic target for the treatment of disorders such as obesity and at the other extreme, anorexia. Due to the initial lack of pharmacological tools that are active in vivo, functions of the different Y receptors have been mainly studied in knockout and transgenic mouse models. However, over recent years various Y receptor selective peptidic and non-peptidic agonists and antagonists have been developed and tested. Their therapeutic potential in relation to treating obesity and other disorders of energy homeostasis is discussed in this review.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.